Smith & Nephew unveils wound dressing; Abbott issues another dividend;

@FierceMedDev: InVivo slides again as CFO bolts, spinal study pends. ICYMI yesterday | Follow @FierceMedDev

@DamianFierce: Covidien projects a modest 2014, its first full year with no pharma revenue. Report | Follow @DamianFierce

@MarkHFierce: We have a new round of stories at FierceDiagnostics. Check them out | Follow @MarkHFierce

@MichaelGFierce: This week, in life sciences hiring: Ex-Bausch + Lomb CEO takes helm at Forest Labs... and more. Chutes & Ladders | Follow @MichaelGFierce

> Smith & Nephew ($SNN) has rolled out a new antimicrobial wound dressing in the U.S., made with silver. Item

> Abbott ($ABT) will be issuing its 359th consecutive quarterly dividend, this time at 14 cents per share. Item

> Tyber Medical nailed down a CE mark for its new interbody fusion device. Item

> Cyberonics ($CYBX) has brought on a former St. Jude Medical ($STJ) executive as its new senior vice president of strategic planning. Story

> Emergent Medical Partners has raised $37 million for a fund that will focus on early-stage med tech investing. Item

> DFine gained a CE mark for its Star tumor ablation system that treats metastatic spinal tumors. Item

Biotech News

@FierceBiotech: Trending now: Biotech R&D spending roars ahead as Big Pharma grimly holds the line. ICYMI yesterday | Follow @FierceBiotech

@JohnCFierce: Delcath gets a CRL, a demand for a new trial, some other hurdles, and fires its CEO. Busy day. Release | Follow @JohnCFierce

@EmilyMFierce: NIH partners with Eli Lilly, others on rare diseases. Article | Follow @EmilyMFierce

> Party drug ketamine gains steam for antidepressant use. Item

> Egalet scores up to $20M for next-gen pain drug as FDA aims to block abuse. Story

> Delcath gets FDA denial on cancer treatment and axes CEO. Article

> Visterra's engineered antibody passes preclinical test as universal flu treatment. More

Pharma News

@FiercePharma: Ruling against GSK's Lovaza fish-oil pill puts hurt on competitor Amarin. Story | Follow @FiercePharma

@EricPFierce: South Africa's Aspen says manufacturing assets it is getting from GSK, Merck part of global push. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Is J&J's manufacturing any better off since it pledged to keep closer oversight? Second recall in two weeks. Report | Follow @CarlyHFierce

> Lilly files $500M lawsuit against Canada. News

> Germany's Bayer joins crowd of companies under Chinese investigation. More

> J&J trying to drag Boehringer into arbitration over Doxil production lapses. Article

> FDA panel gives 'historic' thumbs-up to Roche's Perjeta in early breast cancer. News

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.